dalteparin has been researched along with Recrudescence in 200 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 9.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding." | 9.27 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018) |
| "In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0." | 9.22 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. ( Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S, 2016) |
| "The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)." | 9.20 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015) |
| "Major bleeding was less frequent during dalteparin therapy beyond 6 months." | 9.20 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 9.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months." | 9.16 | Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012) |
| "We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism." | 9.13 | Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 9.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis." | 9.11 | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 9.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 9.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 9.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 9.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy." | 7.88 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018) |
| " The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban." | 7.85 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017) |
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 7.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 7.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 7.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 7.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 6.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | 6.82 | Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| " There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs." | 6.79 | Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014) |
| "The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)." | 5.48 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 5.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 5.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality." | 5.30 | Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| "Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding." | 5.27 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018) |
| "In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE." | 5.27 | Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. ( Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI, 2018) |
| "In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0." | 5.22 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment. ( Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S, 2016) |
| "The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)." | 5.20 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015) |
| "Major bleeding was less frequent during dalteparin therapy beyond 6 months." | 5.20 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 5.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months." | 5.16 | Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012) |
| "We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism." | 5.13 | Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| "In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding." | 5.12 | Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. ( Harenberg, J; Jörg, I; Weiss, C, 2006) |
| "Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity." | 5.12 | Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S, 2006) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 5.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis." | 5.11 | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004) |
| "Evaluation of the effectiveness and safety of the low molecular weight heparin (LMWH) tinzaparin versus unfractionated heparin (UFH) followed by acenocoumarol in proximal deep venous thrombosis (DVT)." | 5.11 | Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. ( Daskalopoulos, ME; Daskalopoulou, SS; Dimitroulis, D; Kakissis, I; Liapis, CD; Nikolaou, A; Sfiridis, P; Tzortzis, E, 2005) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 5.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 5.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 5.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
| "1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 5.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "This study was a retrospective pilot analysis of adult patients with gynecologic malignancies who received either rivaroxaban, warfarin or low molecular weight heparin for treatment of venous thromboembolism at Augusta University Medical Center from 1 July 2013 to 30 June 2015." | 3.91 | Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. ( Gandhi, AS; Signorelli, JR, 2019) |
| "Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy." | 3.88 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| " We report a rare case of spontaneous rupture of liver hematoma in patient treated with warfarin end enoxaparin sodium because of pulmonary embolism." | 3.85 | Spontaneous liver rupture associated with anticoagulant therapy A case report. ( Amicucci, G; Clementi, M; Colozzi, S; Della Penna, A; Guadagni, S; Pessia, B; Schietroma, M; Sista, F, 2017) |
| " The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban." | 3.85 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017) |
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 3.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 3.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "Recurrent venous thromboembolism (VTE) occurs in some patients despite treatment with the standard drugs, warfarin and low-molecular-weight heparin (LMWH)." | 3.80 | Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis. ( Thachil, J, 2014) |
| "Treatment with dalteparin reduced the risk of death and myocardial infarction in high-risk (i." | 3.79 | Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial. ( Wallentin, L, 2000) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 3.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| " Coumarin-induced skin necrosis was a recurrent feature during oral anticoagulation therapy, forcing her physicians to treat her with nadroparin (Fraxiparin) for only a few months." | 3.72 | Late onset of clinical symptoms and recurrent ecchymotic skin lesions in a 12-year-old girl with a severe double heterozygous protein C deficiency. ( Alhenc-Gelas, M; Corazza, F; Demulder, A; Ferster, A; Loop, M, 2004) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 3.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 2.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality." | 2.87 | Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | 2.82 | Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| "A total of 284 patients with venous ulcers were recruited in a 4-year period." | 2.80 | Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. ( Amato, B; Buffone, G; de Franciscis, S; Molinari, V; Montemurro, R; Perri, P; Serra, R; Stillitano, DM, 2015) |
| "The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer." | 2.80 | Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. ( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015) |
| "In the group of patients without pulmonary embolism at baseline, 2." | 2.79 | Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. ( Becker, LK; Harenberg, J; Melzer, N; Riess, H, 2014) |
| " There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs." | 2.79 | Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014) |
| "In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care." | 2.76 | Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. ( Aujesky, D; Beer, HJ; Cornuz, J; Egloff, M; Fine, MJ; Hugli, O; Legall, C; N'gako, A; Osterwalder, J; Perrier, A; Pugh, NA; Renaud, B; Righini, M; Roy, PM; Sanchez, O; Stone, RA; Verhamme, P; Verschuren, F; Yealy, DM, 2011) |
| " After initial LMWH, patients received 6 months of treatment with full therapeutic dosage of tinzaparin or acenocoumarol." | 2.74 | A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. ( Bonell, A; Cairols, MA; Colomé, E; Lapiedra, O; Martí, X; Romera, A; Vila-Coll, R, 2009) |
| "Bleeding is associated with adverse outcome in acute coronary syndromes." | 2.73 | Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. ( DeYoung, P; Fitchett, DH; Goodman, SG; Huynh, T; Langer, A; Weeks, A; Yan, AT; Yan, RT, 2008) |
| "Thrombocytopenia is associated with an increased risk for adverse cardiac events and bleeding in patients presenting with acute coronary syndromes (ACS) treated with unfractionated heparin (UFH)." | 2.73 | Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. ( Antman, EM; Bradner, JE; Gibson, CM; Giugliano, RP; Jang, IK; Morrow, DA; Qin, J; Scirica, B; Shui, A; Wiviott, SD; Yeh, RW, 2007) |
| "Incidences of recurrence of thromboembolism and of severe bleeding were assessed at the end of this period." | 2.71 | [Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism]. ( Baloira Villar, A; Golpe Gómez, R; Pajuelo Fernández, F; Pérez de Llano, LA; Veiga, F; Veres Racamonde, A, 2003) |
| "In treated women, the relative risk for preeclampsia was 0." | 2.71 | Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. ( Abbate, R; Fatini, C; Gensini, F; Gensini, GF; Marchionni, M; Mello, G; Parretti, E; Riviello, C; Scarselli, GF, 2005) |
| "Bleedings were all minor, mostly during hospital stay." | 2.69 | Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. ( Barsotti, A; Belcaro, G; Cesarone, MR; Christopoulos, D; Corsi, M; De Sanctis, MT; Incandela, L; Laurora, G; Lennox, A; Malouf, M; Nicolaides, AN; Vasdekis, S, 1999) |
| " However, body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing." | 2.69 | Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. ( Büller, HR; Harenberg, J; Huisman, MV; Koppenhagen, K; Schmidt, JA; Tolle, A, 2000) |
| " However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use." | 2.68 | A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. ( Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J, 1996) |
| "However, its application to pulmonary embolism or previous episodes of thromboembolism has not been studied." | 2.68 | Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. ( Baildon, R; Büller, HR; Gallus, AS; Gent, M; Ginsberg, J; Prins, MH, 1997) |
| "Of these 14 late recurrences, just one occurred in patients with postoperative DVT." | 2.67 | Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. ( Aiello, S; Dettori, AG; Manotti, C; Pattacini, C; Pini, M; Poli, T; Quintavalla, R; Tagliaferri, A, 1994) |
| "Angiographic restenosis was defined as a loss of 50% of the initial gain as measured by quantitative coronary angiography (QCA) at a core laboratory." | 2.67 | Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. ( Califf, R; Coté, G; Dorosti, K; Douglas, J; Faxon, DP; Gordon, JB; Gottlieb, R; Minor, S; Spiro, TE; Topol, E, 1994) |
| "Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE." | 2.58 | Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018) |
| " The dosage of LMWH was performed by body weight adjustment without dose-finding studies." | 2.42 | [Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]. ( Harenberg, J, 2003) |
| "Patients with acute deep vein thrombosis (DVT) were treated with a body-weight independent dosage of 2 x 8000 aXa IU low-molecular-weight heparin (LMWH) Certoparin." | 2.41 | Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis. ( Harenberg, J, 2002) |
| "History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration." | 1.91 | Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin. ( Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S, 2023) |
| "Common VTE risk factors included cancer (46." | 1.62 | Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study. ( Johnson, SA; Jones, AE; Lai, N; Witt, DM, 2021) |
| "Surprisingly, the risk for recurrence was similar in the ACAP and control groups (15%, P > ." | 1.62 | The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis. ( Levi, L; Sapir, E; Soudry, E; Yaniv, D; Zavdy, O, 2021) |
| "Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited." | 1.56 | Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. ( Antonio, M; Domènech, P; Peñafiel, J; Peris, J; Pina, E; Rosselló, E; Tebe, C, 2020) |
| " Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence." | 1.56 | [Antithrombotic Treatment of Pulmonary Embolism]. ( Ebner, M; Lankeit, M, 2020) |
| "The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)." | 1.48 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018) |
| "The rate of VTE recurrences was similar in both subgroups." | 1.46 | Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. ( Bascuñana, J; Bergmann, JF; Bortoluzzi, C; Ferrazzi, P; Giorgi-Pierfranceschi, M; López-Reyes, R; López-Sáez, JB; Monreal, M; Suriñach, JM; Trujillo-Santos, J, 2017) |
| "In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL." | 1.46 | Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. ( Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J, 2017) |
| "Adherence to FDA-approved dosing for the direct oral anticoagulants (DOACs) based on renal function, hepatic function, and concomitant medications in a real-world setting has not been evaluated." | 1.46 | Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. ( Bohm, N; Duckett, A; Fisher, S; Tran, E, 2017) |
| "Venous thrombosis complicating SAPHO syndrome seems to be uncommon with an unclear pathogenesis (3-9)." | 1.43 | Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome. ( Brzosko, M; Przepiera-Będzak, H, 2016) |
| "SVT favors the relapse of esophageal varices, but rebleeding can be effectively prevented by standard scheduled band ligations." | 1.38 | Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. ( Amitrano, L; Guardascione, MA; Lampasi, F; Lanza, AG; Manguso, F; Martino, R; Menchise, A; Scaglione, M, 2012) |
| "We report a case of bilateral pulmonary embolism in a patient of 50 years." | 1.37 | [Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap]. ( Bodian, M; Diack, B; Diao, M; Hakim, R; Kagambèga, LJ; Kane, A; Kane, M; Mbaye, A; Ndiaye, MB; Pessinaba, S; Sow, DD; Yaméogo, NV, 2011) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| " The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin." | 1.35 | ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. ( Giugliano, RP; Thomas, D, 2009) |
| "The cumulative rate of unprovoked recurrence in patients with a positive D-dimer was 20% at 5 years [5." | 1.35 | Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. ( Baglin, C; Baglin, T; Luddington, R; Palmer, CR, 2008) |
| "In patients with malignant tumors not only the incidence of VTE is higher but the course of VTE is more severe and relapses are more frequent." | 1.33 | [Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study]. ( Farkas, E; Köves, I; Mátrai, Z; Péley, G; Rényi-Vámos, F, 2005) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 1.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH)." | 1.31 | Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. ( Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM, 2001) |
| "Home treatment of deep vein thrombosis (DVT) has been shown to be safe and effective." | 1.31 | Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. ( Beyer, J; Schellong, SM; Schmidt, B; Schröder, HE; Schwarz, T, 2001) |
| "The observed recurrence rate of 0." | 1.31 | Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study. ( Bonet, M; Büller, H; Fraile, M; Lensing, AW; Monreal, M; Muchart, J; Roncales, J, 2002) |
| "Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality." | 1.30 | Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 36 (18.00) | 18.2507 |
| 2000's | 87 (43.50) | 29.6817 |
| 2010's | 66 (33.00) | 24.3611 |
| 2020's | 11 (5.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brüggemann, R | 1 |
| Gietema, H | 1 |
| Jallah, B | 1 |
| Ten Cate, H | 1 |
| Stehouwer, C | 1 |
| Spaetgens, B | 1 |
| Serra, R | 1 |
| Buffone, G | 1 |
| Molinari, V | 1 |
| Montemurro, R | 1 |
| Perri, P | 1 |
| Stillitano, DM | 1 |
| Amato, B | 1 |
| de Franciscis, S | 1 |
| Stammler, F | 1 |
| Grau, C | 1 |
| Eckstein, HH | 1 |
| Hartung, O | 1 |
| Miranda, E | 1 |
| Alimi, YS | 1 |
| Juhan, C | 1 |
| Loop, M | 1 |
| Ferster, A | 1 |
| Corazza, F | 1 |
| Alhenc-Gelas, M | 1 |
| Demulder, A | 1 |
| Tsai, NW | 1 |
| Chang, HW | 1 |
| Chang, WN | 1 |
| Huang, CR | 1 |
| Lin, TK | 1 |
| Chen, SD | 1 |
| Lui, CC | 1 |
| Wang, KW | 1 |
| Cheng, BC | 1 |
| Hung, PL | 1 |
| Chang, CS | 1 |
| Lu, CH | 1 |
| Lai, CC | 1 |
| Hu, CJ | 1 |
| Kosior, DA | 1 |
| Torbicki, A | 1 |
| Opolski, G | 1 |
| Pistorius, MA | 1 |
| Said, L | 1 |
| Planchon, B | 1 |
| Tschammler, A | 1 |
| Markert, T | 1 |
| Wittenberg, G | 1 |
| Krahe, T | 1 |
| Barkagan, ZS | 1 |
| Koopman, MM | 1 |
| Prandoni, P | 3 |
| Piovella, F | 3 |
| Ockelford, PA | 1 |
| Brandjes, DP | 1 |
| van der Meer, J | 1 |
| Gallus, AS | 5 |
| Simonneau, G | 3 |
| Chesterman, CH | 1 |
| Prins, MH | 8 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Lewandowski, K | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 2 |
| Hirsh, J | 2 |
| Lablanche, JM | 2 |
| McFadden, EP | 1 |
| Meneveau, N | 1 |
| Lusson, JR | 1 |
| Bertrand, B | 1 |
| Metzger, JP | 1 |
| Legrand, V | 1 |
| Grollier, G | 1 |
| Macaya, C | 1 |
| de Bruyne, B | 1 |
| Vahanian, A | 1 |
| Grentzinger, A | 1 |
| Masquet, C | 1 |
| Wolf, JE | 1 |
| Tobelem, G | 1 |
| Fontecave, S | 1 |
| Vacheron, A | 1 |
| d'Azemar, P | 1 |
| Bertrand, ME | 1 |
| Godoy, I | 1 |
| Herrera, C | 1 |
| Zapata, C | 1 |
| Kunstmann, S | 1 |
| Abufhele, A | 1 |
| Corbalán, R | 1 |
| Belcaro, G | 1 |
| Nicolaides, AN | 1 |
| Cesarone, MR | 1 |
| Laurora, G | 1 |
| De Sanctis, MT | 1 |
| Incandela, L | 1 |
| Barsotti, A | 1 |
| Corsi, M | 1 |
| Vasdekis, S | 4 |
| Christopoulos, D | 1 |
| Lennox, A | 1 |
| Malouf, M | 1 |
| Borja, J | 1 |
| Olivella, P | 1 |
| Grau, E | 1 |
| Tenias, JM | 1 |
| Real, E | 1 |
| Medrano, J | 1 |
| Ferrer, R | 1 |
| Pastor, E | 1 |
| Selfa, S | 1 |
| Horne, MK | 1 |
| Couturaud, F | 2 |
| Julian, JA | 1 |
| Kearon, C | 1 |
| Schwarz, T | 1 |
| Schmidt, B | 1 |
| Beyer, J | 1 |
| Schröder, HE | 1 |
| Schellong, SM | 1 |
| Cosmi, B | 2 |
| Filippini, M | 2 |
| Campana, F | 1 |
| Avruscio, G | 2 |
| Ghirarduzzi, A | 2 |
| Bucherini, E | 2 |
| Camporese, G | 2 |
| Imberti, D | 2 |
| Legnani, C | 1 |
| Palareti, G | 2 |
| Tonti, D | 1 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Pina, E | 1 |
| Antonio, M | 1 |
| Peris, J | 1 |
| Rosselló, E | 1 |
| Domènech, P | 1 |
| Peñafiel, J | 1 |
| Tebe, C | 1 |
| Sudhakar, D | 1 |
| Kamran, H | 1 |
| Chen, N | 1 |
| Mims, M | 1 |
| Hamzeh, I | 1 |
| Chuzi, S | 1 |
| Eucalitto, P | 1 |
| Yee, LM | 1 |
| Lai, N | 1 |
| Jones, AE | 1 |
| Johnson, SA | 1 |
| Witt, DM | 1 |
| Yaniv, D | 1 |
| Zavdy, O | 1 |
| Sapir, E | 1 |
| Levi, L | 1 |
| Soudry, E | 1 |
| Lv, Y | 1 |
| Bai, W | 1 |
| Li, K | 1 |
| Wang, Z | 1 |
| Guo, W | 1 |
| Luo, B | 1 |
| Wang, J | 1 |
| Wang, Q | 1 |
| Wang, E | 1 |
| Xia, D | 1 |
| Li, X | 1 |
| Yuan, J | 1 |
| Han, N | 1 |
| Niu, J | 1 |
| Yin, Z | 1 |
| Fan, D | 1 |
| Han, G | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 5 |
| Halvorsen, S | 2 |
| Steg, PG | 1 |
| Van de Werf, F | 5 |
| Armstrong, PW | 6 |
| Clementi, M | 1 |
| Colozzi, S | 1 |
| Guadagni, S | 1 |
| Pessia, B | 1 |
| Sista, F | 1 |
| Schietroma, M | 1 |
| Della Penna, A | 1 |
| Amicucci, G | 1 |
| Alzghari, SK | 1 |
| Seago, SE | 1 |
| Garza, JE | 1 |
| Hashimie, YF | 1 |
| Baty, KA | 1 |
| Evans, MF | 1 |
| Shaver, C | 1 |
| Herrington, JD | 1 |
| Nam, KW | 1 |
| Kim, CK | 1 |
| Kim, TJ | 1 |
| An, SJ | 1 |
| Oh, K | 1 |
| Ko, SB | 1 |
| Yoon, BW | 1 |
| Signorelli, JR | 1 |
| Gandhi, AS | 1 |
| Yee, MK | 1 |
| Nafee, T | 1 |
| Daaboul, Y | 1 |
| Korjian, S | 1 |
| AlKhalfan, F | 1 |
| Kerneis, M | 1 |
| Wiest, C | 1 |
| Goldhaber, SZ | 2 |
| Hernandez, AF | 1 |
| Hull, RD | 3 |
| Cohen, AT | 4 |
| Harrington, RA | 2 |
| Gibson, CM | 4 |
| Nicklaus, MD | 1 |
| Ludwig, SL | 1 |
| Kettle, JK | 1 |
| Alva, H | 1 |
| Goyeneche, N | 1 |
| Fletcher, M | 1 |
| Warrier, R | 1 |
| Stepien, K | 1 |
| Nowak, K | 1 |
| Zalewski, J | 1 |
| Pac, A | 1 |
| Undas, A | 1 |
| Wysokinski, WE | 2 |
| Houghton, DE | 1 |
| Casanegra, AI | 1 |
| Vlazny, DT | 1 |
| Bott-Kitslaar, DM | 1 |
| Froehling, DA | 1 |
| Hodge, DO | 1 |
| Peterson, LG | 1 |
| Mcbane, RD | 1 |
| Gershlick, AH | 1 |
| Goldstein, P | 3 |
| Wilcox, R | 1 |
| Danays, T | 2 |
| Lambert, Y | 1 |
| Sulimov, V | 1 |
| Rosell Ortiz, F | 1 |
| Ostojic, M | 1 |
| Welsh, RC | 1 |
| Carvalho, AC | 1 |
| Nanas, J | 1 |
| Arntz, HR | 1 |
| Grajek, S | 1 |
| Fresco, C | 1 |
| Bluhmki, E | 1 |
| Regelin, A | 1 |
| Vandenberghe, K | 1 |
| Bogaerts, K | 2 |
| Lucania, G | 1 |
| Camiolo, E | 1 |
| Carmina, MG | 1 |
| Fiandaca, T | 1 |
| Indovina, A | 1 |
| Malato, A | 1 |
| Messina, R | 1 |
| Fabbiano, F | 1 |
| Marcenò, R | 1 |
| Königsbrügge, O | 1 |
| Langer, M | 1 |
| Hayde, M | 1 |
| Ay, C | 1 |
| Pabinger, I | 3 |
| Ozdemir, MA | 1 |
| Işik, B | 1 |
| Patiroglu, T | 1 |
| Karakukcu, M | 1 |
| Mutlu, FT | 1 |
| Yilmaz, E | 1 |
| Unal, E | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Patel, AA | 1 |
| Ogden, K | 1 |
| Mody, SH | 1 |
| Bookhart, B | 1 |
| Kooistra, HA | 1 |
| Gebel, M | 2 |
| Sahin, K | 1 |
| Lensing, AW | 7 |
| Meijer, K | 1 |
| Leguísamo, S | 1 |
| Prados Castaño, M | 1 |
| Piñero Saavedra, M | 1 |
| Cimbollek, S | 1 |
| Agnelli, G | 3 |
| Buller, HR | 11 |
| Cohen, A | 2 |
| Lee, TC | 1 |
| Pak, R | 1 |
| Raskob, GE | 7 |
| Weitz, JI | 5 |
| Yamabe, T | 1 |
| Sanders, P | 1 |
| Thompson, JR | 1 |
| Ramacciotti, E | 2 |
| Martinelli, I | 1 |
| Middeldorp, S | 3 |
| Levi, M | 2 |
| Beyer-Westendorf, J | 5 |
| van Bellen, B | 1 |
| Bounameaux, H | 4 |
| Brighton, TA | 1 |
| Trajanovic, M | 1 |
| Lam, P | 1 |
| Wells, PS | 4 |
| Beato, J | 1 |
| Fígueira, L | 1 |
| Penas, S | 1 |
| Santos-Silva, R | 1 |
| Falcão, M | 1 |
| Carneiro, Â | 1 |
| Reis, FF | 1 |
| Di Nisio, M | 5 |
| Vedovati, MC | 1 |
| Riera-Mestre, A | 1 |
| Mueller, K | 1 |
| Kubitza, D | 1 |
| Schneider, J | 1 |
| Pisters, R | 1 |
| Fedacko, J | 1 |
| Fontes-Carvalho, R | 1 |
| Cheung, YW | 1 |
| Pap, AF | 1 |
| Ten Cate-Hoek, AJ | 1 |
| Villalta, S | 1 |
| Milan, M | 1 |
| Verhamme, P | 6 |
| Bauersachs, RM | 1 |
| Pignataro, BS | 1 |
| Nishinari, K | 1 |
| Cavalcante, RN | 1 |
| Centofanti, G | 1 |
| Yazbek, G | 1 |
| Krutman, M | 1 |
| Bomfim, GAZ | 1 |
| Fonseca, IYI | 1 |
| Teivelis, MP | 1 |
| Wolosker, N | 1 |
| Sanches, SM | 1 |
| Trujillo-Santos, J | 1 |
| Bergmann, JF | 1 |
| Bortoluzzi, C | 1 |
| López-Reyes, R | 1 |
| Giorgi-Pierfranceschi, M | 1 |
| López-Sáez, JB | 1 |
| Ferrazzi, P | 1 |
| Bascuñana, J | 1 |
| Suriñach, JM | 1 |
| Monreal, M | 5 |
| Przepiera-Będzak, H | 1 |
| Brzosko, M | 1 |
| Mantha, S | 1 |
| Miao, Y | 1 |
| Wills, J | 1 |
| Parameswaran, R | 1 |
| Soff, GA | 1 |
| Tran, E | 1 |
| Duckett, A | 1 |
| Fisher, S | 1 |
| Bohm, N | 1 |
| González-Fajardo, JA | 1 |
| Martin-Pedrosa, M | 1 |
| Castrodeza, J | 1 |
| Tamames, S | 1 |
| Vaquero-Puerta, C | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Yan, AT | 1 |
| Yan, RT | 1 |
| Huynh, T | 1 |
| DeYoung, P | 1 |
| Weeks, A | 1 |
| Fitchett, DH | 1 |
| Langer, A | 5 |
| Goodman, SG | 4 |
| Thomas, D | 1 |
| Giugliano, RP | 3 |
| Deitelzweig, SB | 1 |
| Becker, R | 1 |
| Lin, J | 1 |
| Benner, J | 1 |
| Saland, JM | 1 |
| Shneider, BL | 1 |
| Bromberg, JS | 1 |
| Shi, PA | 1 |
| Ward, SC | 1 |
| Magid, MS | 1 |
| Benchimol, C | 1 |
| Seikaly, MG | 1 |
| Emre, SH | 1 |
| Bresin, E | 1 |
| Remuzzi, G | 1 |
| Zeymer, U | 2 |
| Gitt, A | 1 |
| Zahn, R | 1 |
| Jünger, C | 1 |
| Bauer, T | 1 |
| Heer, T | 1 |
| Koeth, O | 1 |
| Senges, J | 1 |
| Laalou, FZ | 1 |
| Kuntzmann, H | 1 |
| Mahoudeau, G | 1 |
| Kremer, S | 1 |
| Pain, L | 1 |
| Love, BL | 1 |
| Kehr, H | 1 |
| Olin, JL | 1 |
| Giraldez, RR | 1 |
| Morrow, DA | 5 |
| Antman, EM | 7 |
| Mohanavelu, S | 1 |
| Murphy, SA | 4 |
| McCabe, CH | 5 |
| Braunwald, E | 6 |
| Yaméogo, NV | 1 |
| Mbaye, A | 1 |
| Kagambèga, LJ | 1 |
| Diack, B | 1 |
| Pessinaba, S | 1 |
| Hakim, R | 1 |
| Ndiaye, MB | 1 |
| Bodian, M | 1 |
| Diao, M | 1 |
| Sow, DD | 1 |
| Kane, M | 1 |
| Kane, A | 1 |
| Landman, GW | 1 |
| Gans, RO | 1 |
| Howard, L | 1 |
| Salooja, N | 1 |
| Aujesky, D | 1 |
| Roy, PM | 1 |
| Verschuren, F | 1 |
| Righini, M | 1 |
| Osterwalder, J | 1 |
| Egloff, M | 1 |
| Renaud, B | 1 |
| Stone, RA | 1 |
| Legall, C | 1 |
| Sanchez, O | 2 |
| Pugh, NA | 1 |
| N'gako, A | 1 |
| Cornuz, J | 1 |
| Hugli, O | 1 |
| Beer, HJ | 1 |
| Perrier, A | 1 |
| Fine, MJ | 1 |
| Yealy, DM | 1 |
| Vorob'eva, NM | 1 |
| Panchenko, EP | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Ermolina, OV | 1 |
| Balakhonova, TV | 1 |
| Kirienko, AI | 1 |
| Montalescot, G | 2 |
| Silvain, J | 1 |
| Boulanger, B | 1 |
| Cohen, M | 9 |
| Ecollan, P | 1 |
| Combes, X | 1 |
| Pollack, C | 1 |
| Bénezet, JF | 1 |
| Stibbe, O | 1 |
| Filippi, E | 1 |
| Teiger, E | 1 |
| Cayla, G | 1 |
| Elhadad, S | 1 |
| Adnet, F | 1 |
| Chouihed, T | 1 |
| Gallula, S | 1 |
| Greffet, A | 1 |
| Aout, M | 1 |
| Collet, JP | 1 |
| Vicaut, E | 1 |
| Lensin, AW | 1 |
| Decousus, H | 6 |
| Jacobson, BF | 1 |
| Minar, E | 1 |
| Chlumsky, J | 2 |
| Wells, P | 1 |
| Berkowitz, SD | 1 |
| Davidson, BL | 4 |
| Misselwitz, F | 2 |
| Schellong, S | 1 |
| Segers, A | 5 |
| Amitrano, L | 1 |
| Guardascione, MA | 1 |
| Scaglione, M | 1 |
| Menchise, A | 1 |
| Martino, R | 1 |
| Manguso, F | 1 |
| Lanza, AG | 1 |
| Lampasi, F | 1 |
| Reich-Schupke, S | 1 |
| Doerler, M | 1 |
| Altmeyer, P | 1 |
| Stücker, M | 1 |
| Simoons, M | 1 |
| Krzemiñska-Pakula, M | 2 |
| Alonso, A | 1 |
| Goodman, S | 3 |
| Kali, A | 1 |
| Loos, U | 1 |
| Gosset, F | 1 |
| Louer, V | 1 |
| Bigonzi, F | 5 |
| Findik, S | 1 |
| Erkan, ML | 1 |
| Selçuk, MB | 1 |
| Albayrak, S | 1 |
| Atici, AG | 1 |
| Doru, F | 1 |
| Fitchett, D | 1 |
| Gupta, M | 1 |
| Pérez de Llano, LA | 1 |
| Baloira Villar, A | 1 |
| Veres Racamonde, A | 1 |
| Veiga, F | 1 |
| Golpe Gómez, R | 1 |
| Pajuelo Fernández, F | 1 |
| Michalis, LK | 1 |
| Katsouras, CS | 1 |
| Papamichael, N | 1 |
| Adamides, K | 1 |
| Naka, KK | 1 |
| Goudevenos, J | 1 |
| Sideris, DA | 1 |
| Streif, W | 1 |
| Goebel, G | 1 |
| Chan, AK | 1 |
| Massicotte, MP | 1 |
| Dubois, CL | 1 |
| Belmans, A | 1 |
| Granger, CB | 5 |
| Wallentin, L | 5 |
| Fioretti, PM | 1 |
| López-Sendón, JL | 2 |
| Verheugt, FW | 1 |
| Meyer, J | 1 |
| Gensini, GF | 3 |
| Maritz, F | 2 |
| Gurfinkel, EP | 6 |
| Timerman, A | 2 |
| Danchin, N | 2 |
| White, HD | 3 |
| Santopinto, J | 1 |
| Hecquet, C | 1 |
| Vittori, L | 2 |
| Bijsterveld, NR | 2 |
| Peters, RJ | 3 |
| Bernink, PJ | 2 |
| Tijssen, JG | 2 |
| Gallus, A | 2 |
| Gent, M | 4 |
| Raskob, G | 4 |
| Segers, AE | 2 |
| Cariou, R | 1 |
| Leeuwenkamp, O | 1 |
| Jiang, F | 2 |
| Fox, KA | 8 |
| Sharma, D | 1 |
| Chew, P | 1 |
| Kaul, P | 1 |
| Cowper, PA | 1 |
| Eisenstein, EL | 1 |
| Mark, DB | 1 |
| Farkas, E | 1 |
| Péley, G | 1 |
| Mátrai, Z | 1 |
| Rényi-Vámos, F | 1 |
| Köves, I | 1 |
| Mismetti, P | 1 |
| Quenet, S | 1 |
| Levine, M | 2 |
| Merli, G | 2 |
| Derobert, E | 1 |
| Laporte, S | 2 |
| Harenberg, J | 7 |
| Jörg, I | 1 |
| Weiss, C | 1 |
| Yusuf, S | 2 |
| Mehta, SR | 2 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Pogue, J | 1 |
| Budaj, A | 2 |
| Bassand, JP | 1 |
| Joyner, C | 1 |
| Ruda, M | 1 |
| Sadowski, Z | 1 |
| Guneri, S | 1 |
| Bischoff, A | 1 |
| Chang, WC | 1 |
| Palumbo, A | 1 |
| Rus, C | 1 |
| Zeldis, JB | 1 |
| Rodeghiero, F | 1 |
| Boccadoro, M | 1 |
| Alexander, JH | 1 |
| Shorr, AF | 1 |
| Jackson, WL | 1 |
| Moores, LK | 1 |
| Warkentin, TE | 1 |
| Ardissino, D | 1 |
| Gulba, DC | 1 |
| Kracoff, OH | 1 |
| Lewis, BS | 1 |
| Roguin, N | 1 |
| Di Gennaro, L | 1 |
| Maggi, F | 1 |
| Novarese, L | 1 |
| Cipriani, MC | 1 |
| Bonomo, L | 1 |
| Landolfi, R | 1 |
| Yeh, RW | 1 |
| Wiviott, SD | 1 |
| Shui, A | 1 |
| Qin, J | 1 |
| Scirica, B | 1 |
| Bradner, JE | 1 |
| Jang, IK | 1 |
| Kinori, M | 1 |
| Saar, N | 1 |
| Justo, D | 1 |
| Almog, R | 1 |
| Baglin, T | 1 |
| Palmer, CR | 1 |
| Luddington, R | 1 |
| Baglin, C | 1 |
| Pini, M | 1 |
| Aiello, S | 1 |
| Manotti, C | 1 |
| Pattacini, C | 1 |
| Quintavalla, R | 1 |
| Poli, T | 1 |
| Tagliaferri, A | 1 |
| Dettori, AG | 1 |
| Faxon, DP | 1 |
| Spiro, TE | 2 |
| Minor, S | 1 |
| Coté, G | 1 |
| Douglas, J | 1 |
| Gottlieb, R | 1 |
| Califf, R | 1 |
| Dorosti, K | 1 |
| Topol, E | 1 |
| Gordon, JB | 1 |
| Leclerc, J | 1 |
| Anderson, D | 1 |
| Weitz, J | 2 |
| Ginsberg, J | 2 |
| Turpie, AG | 5 |
| Demers, C | 3 |
| Kovacs, M | 1 |
| Glick, A | 1 |
| Kornowski, R | 2 |
| Michowich, Y | 1 |
| Koifman, B | 1 |
| Roth, A | 1 |
| Laniado, S | 1 |
| Keren, G | 1 |
| Force, RW | 1 |
| Fromell, GJ | 4 |
| Califf, RM | 3 |
| Premmereur, J | 3 |
| Leadley, RJ | 2 |
| Kasiewski, CJ | 2 |
| Bostwick, JS | 2 |
| Bentley, R | 2 |
| McVey, MJ | 1 |
| White, FJ | 1 |
| Perrone, MH | 2 |
| Dunwiddie, CT | 2 |
| Leizorovicz, A | 1 |
| Parent, F | 1 |
| Page, Y | 2 |
| Tardy, B | 1 |
| Girard, P | 1 |
| Faivre, R | 1 |
| Charbonnier, B | 2 |
| Barral, FG | 1 |
| Huet, Y | 1 |
| Sacks, DB | 1 |
| Rifai, N | 1 |
| Cannon, CP | 1 |
| Salein, D | 1 |
| Bayes De Luna, A | 1 |
| Fox, K | 1 |
| Radley, D | 1 |
| Ellis, MH | 1 |
| Manor, Y | 1 |
| Witz, M | 1 |
| Stinnett, SS | 1 |
| Weatherley, BD | 1 |
| Barr, A | 1 |
| Sobtchouk, A | 1 |
| Laperrière, L | 1 |
| Hill, C | 1 |
| White, H | 1 |
| Le-Louer, V | 1 |
| Nahlawi, M | 1 |
| Benzuly, K | 1 |
| Fintel, D | 1 |
| Olsson, CG | 1 |
| Abildgaard, U | 1 |
| Eldor, A | 1 |
| Elias, D | 1 |
| Grigg, A | 1 |
| Musset, D | 1 |
| Rodgers, GM | 1 |
| Trowbridge, AA | 1 |
| Yusen, RD | 1 |
| Nuijten, MJ | 1 |
| Berto, P | 1 |
| Kosa, J | 1 |
| Nadipelli, V | 1 |
| Cimminiello, C | 1 |
| Spreafico, A | 1 |
| Baird, SH | 1 |
| Menown, IB | 1 |
| Mcbride, SJ | 1 |
| Trouton, TG | 1 |
| Wilson, C | 1 |
| Sarasin, FP | 1 |
| Breddin, HK | 3 |
| Kadziola, Z | 2 |
| Scully, M | 2 |
| Nakov, R | 2 |
| Kakkar, VV | 2 |
| Xie, C | 1 |
| Ahmed, RJ | 1 |
| Xavier, D | 1 |
| Pais, P | 1 |
| Zhu, J | 1 |
| Liu, L | 1 |
| de Bièvre, MA | 1 |
| Vrij, AA | 1 |
| Schoon, EJ | 1 |
| Dijkstra, G | 1 |
| de Jong, AE | 1 |
| Oberndorff-Klein Woolthuis, AH | 1 |
| Hemker, HC | 1 |
| Stockbrügger, RW | 1 |
| Preisack, MB | 3 |
| Karsch, KR | 4 |
| Baumbach, A | 1 |
| Oberhoff, M | 1 |
| Rübsamen, K | 1 |
| Jochims, K | 1 |
| Herdeg, C | 1 |
| Kranzhöfer, A | 1 |
| Safer, A | 1 |
| Baildon, R | 3 |
| Eschenfelder, V | 2 |
| Foley, D | 2 |
| Garcia, EJ | 1 |
| Kaltenbach, M | 2 |
| Meisner, C | 2 |
| Selbmann, HK | 2 |
| Serruys, PW | 2 |
| Shiu, MF | 2 |
| Sujatta, M | 2 |
| Bonan, R | 2 |
| Garcia, E | 1 |
| Göttman, D | 1 |
| Strecker, EP | 1 |
| Boos, I | 1 |
| Vetter, S | 1 |
| Hoppenstead, DA | 1 |
| Fareed, J | 1 |
| Riess, H | 2 |
| Becker, LK | 1 |
| Melzer, N | 1 |
| Koppenhagen, K | 2 |
| Tolle, A | 2 |
| Kemkes-Matthes, B | 1 |
| Gräve, M | 2 |
| Patek, F | 1 |
| Drexler, M | 1 |
| Siemens, HJ | 1 |
| Weidinger, G | 2 |
| Brom, J | 2 |
| Haas, S | 1 |
| Schmidt, JA | 1 |
| Huisman, MV | 3 |
| Diener, HC | 1 |
| Ringelstein, EB | 2 |
| von Kummer, R | 1 |
| Langohr, HD | 1 |
| Bewermeyer, H | 1 |
| Landgraf, H | 1 |
| Hennerici, M | 1 |
| Welzel, D | 1 |
| Tolle, AR | 1 |
| Kirchmaier, CM | 1 |
| Han, JM | 1 |
| Koh, Y | 1 |
| Kim, SH | 1 |
| Suh, SY | 1 |
| Cho, YS | 1 |
| Lee, JH | 1 |
| Yu, SJ | 1 |
| Yoon, JH | 1 |
| Gwak, HS | 1 |
| Ebner, M | 1 |
| Lankeit, M | 1 |
| Riaz, IB | 1 |
| Marshall, AL | 1 |
| Badgett, RG | 1 |
| McBane Ii, R | 1 |
| Loprinzi, CL | 1 |
| Ashrani, A | 1 |
| Perez-Botero, J | 1 |
| Leon Ferre, RA | 1 |
| Henkin, S | 1 |
| Lenz, CJ | 1 |
| Le-Rademacher, JG | 1 |
| van Es, N | 4 |
| Carrier, M | 5 |
| Garcia, D | 4 |
| Grosso, MA | 2 |
| Kakkar, AK | 3 |
| Kovacs, MJ | 4 |
| Mercuri, MF | 3 |
| Meyer, G | 6 |
| Shi, M | 1 |
| Wang, TF | 3 |
| Yeo, E | 1 |
| Zhang, G | 2 |
| Zwicker, JI | 2 |
| Hakoum, MB | 1 |
| Kahale, LA | 1 |
| Tsolakian, IG | 1 |
| Matar, CF | 1 |
| Yosuico, VE | 1 |
| Terrenato, I | 1 |
| Sperati, F | 1 |
| Barba, M | 1 |
| Schünemann, H | 1 |
| Akl, EA | 1 |
| Khorana, AA | 4 |
| Noble, S | 1 |
| Lee, AYY | 3 |
| Soff, G | 1 |
| O'Connell, C | 1 |
| Kraaijpoel, N | 1 |
| Mulder, FI | 1 |
| Grosso, M | 1 |
| Hernandez, CR | 1 |
| Santamaria, A | 1 |
| Schwocho, L | 2 |
| Buller, H | 2 |
| Miyazaki, Y | 1 |
| Sase, K | 1 |
| Hasegawa, K | 1 |
| Morimoto, T | 1 |
| Ragsdell, B | 1 |
| Thachil, J | 3 |
| Hecking, C | 1 |
| Hendelmeier, M | 1 |
| von Bardeleben, R | 1 |
| Gröschel, K | 1 |
| Schinzel, H | 2 |
| O'Brien, SH | 1 |
| Kulkarni, R | 1 |
| Wallace, A | 1 |
| Hamblin, F | 1 |
| Burr, S | 1 |
| Goldenberg, NA | 1 |
| Madahar, P | 1 |
| Gonzalez, CM | 1 |
| Francis, CW | 1 |
| Kessler, CM | 1 |
| Bergqvist, D | 1 |
| Ortel, TL | 1 |
| Spyropoulos, AC | 1 |
| Bleker, SM | 1 |
| Kakkar, A | 1 |
| Boda, Z | 1 |
| Gibbs, H | 1 |
| Kamphuisen, PW | 4 |
| Ockelford, P | 1 |
| Dranitsaris, G | 2 |
| Shane, L | 1 |
| Burgers, L | 1 |
| Woodruff, S | 2 |
| Shane, LG | 1 |
| Galanaud, JP | 1 |
| Stemer, G | 1 |
| Debourdeau, P | 1 |
| Bonet, M | 1 |
| Roncales, J | 1 |
| Muchart, J | 1 |
| Fraile, M | 1 |
| Bergstrand, L | 1 |
| Dellborg, M | 1 |
| Fellenius, C | 1 |
| Lindahl, B | 1 |
| Lins, LE | 1 |
| Nilsson, T | 1 |
| Pehrsson, K | 1 |
| Siegbahn, A | 1 |
| Swahn, E | 1 |
| Mello, G | 1 |
| Parretti, E | 1 |
| Fatini, C | 1 |
| Riviello, C | 1 |
| Gensini, F | 1 |
| Marchionni, M | 1 |
| Scarselli, GF | 1 |
| Abbate, R | 1 |
| Al-Yaseen, E | 1 |
| Anderson, J | 1 |
| Martin, J | 1 |
| Glikson, M | 1 |
| Hasdai, D | 1 |
| Chernine, A | 1 |
| Ohad, D | 1 |
| Battler, A | 1 |
| Lafoz, E | 1 |
| Olive, A | 1 |
| del Rio, L | 1 |
| Vedia, C | 1 |
| Voisard, R | 1 |
| Seitzer, U | 1 |
| Baur, R | 1 |
| Dartsch, PC | 1 |
| Osterhues, H | 1 |
| Höher, M | 1 |
| Hombach, V | 1 |
| Kher, A | 1 |
| Samama, MM | 1 |
| Savage, KJ | 1 |
| Schulz, V | 1 |
| Goudie, D | 1 |
| Morrow, B | 1 |
| Cruickshank, M | 1 |
| Berge, E | 1 |
| Abdelnoor, M | 1 |
| Nakstad, PH | 1 |
| Sandset, PM | 1 |
| Häfeli, R | 1 |
| Kraljevic, S | 1 |
| Wehrli, C | 1 |
| Goede, J | 1 |
| Conen, D | 1 |
| Moons, AH | 1 |
| Meijers, JC | 1 |
| Bahlmann, F | 1 |
| Peetz, D | 1 |
| Savvidis, S | 1 |
| Himmrich, L | 1 |
| Klotz, M | 1 |
| Karathanos, C | 3 |
| Kakkos, SK | 3 |
| Georgiadis, G | 3 |
| Ioannou, C | 3 |
| Chatzis, D | 3 |
| Latzios, P | 3 |
| Giannoukas, AD | 3 |
| Bauersachs, R | 3 |
| Janas, MS | 3 |
| Jarner, MF | 3 |
| Noel-Savina, E | 1 |
| Descourt, R | 1 |
| André, M | 1 |
| Leroyer, C | 1 |
| Lee, AY | 1 |
| Romera, A | 1 |
| Cairols, MA | 1 |
| Vila-Coll, R | 1 |
| Martí, X | 1 |
| Colomé, E | 1 |
| Bonell, A | 1 |
| Lapiedra, O | 1 |
| Pineo, GF | 2 |
| Brant, R | 1 |
| Liang, J | 1 |
| Cook, R | 2 |
| Solymoss, S | 2 |
| Poon, MC | 2 |
| Viguier, JB | 1 |
| Amraoui, S | 1 |
| Solanilla, A | 1 |
| Boulon, C | 1 |
| Constans, J | 1 |
| Conri, C | 1 |
| Geeganage, C | 1 |
| Tracy, M | 1 |
| England, T | 1 |
| Sare, G | 1 |
| Moulin, T | 1 |
| Woimant, F | 1 |
| Christensen, H | 1 |
| De Deyn, PP | 1 |
| Leys, D | 1 |
| O'Neill, D | 1 |
| Bath, PM | 1 |
| Daskalopoulos, ME | 1 |
| Daskalopoulou, SS | 1 |
| Tzortzis, E | 1 |
| Sfiridis, P | 1 |
| Nikolaou, A | 1 |
| Dimitroulis, D | 1 |
| Kakissis, I | 1 |
| Liapis, CD | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Amathieu, R | 1 |
| Tual, L | 1 |
| Fessenmeyer, C | 1 |
| Dhonneur, G | 1 |
| Brant, RF | 1 |
| Mah, AF | 1 |
| Burke, N | 1 |
| Dear, R | 1 |
| Wong, T | 1 |
| Sors, H | 1 |
| Laaban, JP | 1 |
| Azarian, R | 1 |
| Laurent, M | 1 |
| Hirsch, JL | 1 |
| Ferrari, E | 1 |
| Bosson, JL | 1 |
| Mottier, D | 1 |
| Beau, B | 1 |
| Rose, P | 1 |
| Bell, D | 1 |
| Green, ES | 1 |
| Davenport, A | 1 |
| Fegan, C | 1 |
| Grech, H | 1 |
| O'Shaughnessy, D | 1 |
| Voke, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)[NCT00203580] | Phase 4 | 910 participants | Interventional | 1994-12-31 | Completed | ||
| LITE Study, Appendix A (HOME-LITE), Amendment 6[NCT00203658] | Phase 4 | 400 participants | Interventional | 1997-04-30 | Completed | ||
| Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism[NCT02355548] | 200 participants (Anticipated) | Observational | 2012-12-31 | Completed | |||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction[NCT02777580] | Phase 4 | 609 participants (Actual) | Interventional | 2017-08-01 | Active, not recruiting | ||
| Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial[NCT04717986] | 188 participants (Actual) | Interventional | 2021-01-26 | Completed | |||
| Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.[NCT02090712] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2010-01-31 | Enrolling by invitation | |||
| Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00439777] | Phase 3 | 4,833 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00440193] | Phase 3 | 3,449 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)[NCT02811237] | 1,975 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial[NCT00425542] | Phase 3 | 343 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events[NCT00718471] | Phase 3 | 910 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion[NCT03630055] | Phase 3 | 1,800 participants (Anticipated) | Interventional | 2018-10-03 | Recruiting | ||
| The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)[NCT03977363] | 25 participants (Actual) | Observational [Patient Registry] | 2020-01-27 | Terminated (stopped due to Halted Prematurely) | |||
| Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women[NCT02829957] | Phase 2/Phase 3 | 19 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD[NCT03277001] | 438 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | |||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)[NCT00413504] | 30 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Trousseau Studie, Mortaliteit Door Maligniteit Bij patiënten Met Idiopatische Veneuze Tromboembolie[NCT01088334] | 630 participants (Actual) | Observational | 2002-12-31 | Terminated (stopped due to Terminated because of futility to continue, after planned interim analysis.) | |||
| An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815] | Phase 3 | 20,078 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolyt[NCT00077792] | Phase 3 | 20,506 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study[NCT00457158] | Phase 4 | 399 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial[NCT03070834] | 42 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374] | 40 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke[NCT03151993] | Phase 3 | 336 participants (Actual) | Interventional | 2017-03-18 | Completed | ||
| Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients[NCT02301910] | Phase 3 | 392 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism[NCT02585713] | Phase 3 | 300 participants (Actual) | Interventional | 2015-11-20 | Completed | ||
| Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855] | 240 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682] | Phase 3 | 1,046 participants (Actual) | Interventional | 2015-07-16 | Completed | ||
| A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity[NCT00216866] | Phase 2 | 70 participants | Interventional | 2002-09-30 | Completed | ||
| Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025] | Phase 3 | 900 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.2 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.4 |
| Enoxaparin/VKA | 4.0 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.4 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin/VKA | 4.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 10.3 |
| Enoxaparin/VKA | 11.4 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Enoxaparin/VKA | 0.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Enoxaparin/VKA | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 3.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 2.1 | 0.8 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.6 | 1.2 | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.05 | 0 | 0.5 | 0.1 | 0.09 | 0.05 | 0.7 | 0.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.09 | 0 | 0.09 | 0.5 | 0.2 | 0.09 | 0.3 | 0.8 | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0.04 | 0.2 | 0.1 | 0.8 | 0.7 | 0.2 | 0.1 | 1.5 | 2.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.1 | 0.3 | 0.0 | 1.0 | 0.7 | 0.2 | 0.4 | 1.3 | 1.4 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.1 |
| Enoxaparin/VKA | 1.1 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.9 |
| Enoxaparin/VKA | 4.2 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.3 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.6 |
| Enoxaparin/VKA | 4.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.1 |
| Enoxaparin/VKA | 8.1 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.6 |
| Enoxaparin/VKA | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 1.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Enoxaparin/VKA | 0.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 3.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.2 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 5.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 3.0 | 1.1 | 1.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.4 | 1.0 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.07 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.8 | 0.6 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0 | 0.07 | 0 | 0.3 | 0.6 | 0.07 | 0.07 | 1.3 | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.3 | 0 | 1.0 | 1.6 | 0.3 | 0.2 | 2.0 | 1.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.06 | 0.2 | 0.06 | 1.2 | 0.8 | 0.06 | 0.1 | 1.8 | 0.9 |
Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes. (NCT02829957)
Timeframe: 3 months
| Intervention | g/dl (Median) |
|---|---|
| Rivaroxaban | 12.8 |
| Apixaban | 13.25 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 1 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 4 |
| Apixaban | 2 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 1, 2, and 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
"Measure Description: A PBAC Score of < 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;~Towels~1 point for each lightly stained towel~5 points or each moderately soiled towel~20 points if the towel is completely saturated with blood~Tampons~1 point for each lightly stained tampon~5 points for each moderately soiled tampon~10 points if the tampon is completely saturated with blood~Clots~1 point for small clots~5 points for large clots" (NCT02829957)
Timeframe: 3 months
| Intervention | score on a scale (Median) |
|---|---|
| Rivaroxaban | 292 |
| Apixaban | 146 |
The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. (NCT02829957)
Timeframe: 3 months
| Intervention | Score (Median) |
|---|---|
| Rivaroxaban | 55.5 |
| Apixaban | 45.6 |
All-cause mortality (NCT00413374)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin 1.5 mg/kg Once Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 0 |
Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 1 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 0 |
| Arm B (Dalteparin) | 2.1 |
A similar analysis as described for the primary safety analysis will be used. The rate (percentage) of patients experiencing major bleeding or a clinically relevant non-major bleed at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 7.0 |
| Arm B (Dalteparin) | 8.1 |
Analyzed using the same methods described above for the primary endpoint.Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) is defined as the time from randomization to the date the patient experienced the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE). (NCT02585713)
Timeframe: Up to 3 months post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A (Apixaban) | NA |
| Arm B (Dalteparin) | NA |
The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 32 |
| Dalteparin Group | 16 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 67 |
| Dalteparin Group | 71 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 19 |
| Dalteparin Group | 35 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 21 |
| Dalteparin Group | 24 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 41 |
| Dalteparin Group | 59 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 235 |
| Dalteparin Group | 228 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 6 |
| Dalteparin Group | 4 |
14 reviews available for dalteparin and Recrudescence
| Article | Year |
|---|---|
[Per and early postoperative use of low molecular weight heparin in carotid surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis Implantation; Brain Ischemia | 2003 |
[Recurrent pulmonary embolism in the functional loss of an LGM cava filter after the recanalization of a caval thrombosis].
Topics: Aged; Combined Modality Therapy; Equipment Failure; Femoral Vein; Heparin; Humans; Iliac Vein; Male; | 1994 |
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; He | 1996 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari | 2000 |
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hep | 2001 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly | 2002 |
Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmona | 2005 |
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
Topics: Area Under Curve; Drug Therapy, Combination; Emergency Treatment; Enoxaparin; Fibrinolytic Agents; H | 2006 |
Cost-effectiveness of enoxaparin as thromboprophylaxis in acutelly ill medical patients from the Italian NHS perspective.
Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Humans; Recurrence; Thromboembolis | 2002 |
Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis.
Topics: Anticoagulants; Fibrin Fibrinogen Degradation Products; Heparin, Low-Molecular-Weight; Humans; Injec | 2002 |
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage].
Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Hemorrha | 2003 |
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Mol | 2018 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap | 1996 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog | 2000 |
91 trials available for dalteparin and Recrudescence
| Article | Year |
|---|---|
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Drug Administration Schedule; | 2015 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coron | 1997 |
[Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Female; Heparin; Humans; Male; Mid | 1998 |
Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Topics: Ambulatory Care; Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Health Care Costs; | 1999 |
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heparin, Low-Molecular- | 2014 |
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
Topics: Aged; Analysis of Variance; Anticoagulants; Chi-Square Distribution; Dose-Response Relationship, Dru | 2012 |
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
Topics: Adult; Aged; Benzamides; Enoxaparin; Female; Humans; Male; Middle Aged; Pyridines; Recurrence; Secon | 2018 |
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Human | 2019 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fe | 2015 |
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors | 2015 |
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
Topics: Adult; Aged; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; | 2016 |
Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Postt | 2016 |
Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.
Topics: Anticoagulants; Coumarins; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Ag | 2008 |
Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Eptifiba | 2008 |
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Cause of Death; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage | 2010 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study.
Topics: Adult; Aged; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents | 2002 |
Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Injections | 2002 |
[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Prospectiv | 2003 |
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.
Topics: Aged; Angina, Unstable; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2003 |
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Topics: Abciximab; Alberta; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Belgium; | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; | 2003 |
Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave C
Topics: Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weig | 2003 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination; | 2006 |
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Fondapar | 2006 |
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Topics: Aged; Anticoagulants; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolyt | 2006 |
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Mi | 2007 |
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Contraindications; Double-Blind Method | 2007 |
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heparin; Humans; Inc | 2007 |
Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Enoxaparin; Female; Fibrin Fibrinogen De | 1994 |
Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Disease; Do | 1994 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Enoxaparin; Female; Fibrinolytic Ag | 1996 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow- | 1998 |
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Administration Routes; D | 1998 |
Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Disease-Free Survival; Double-Blind Method; Enoxapari | 1999 |
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Creatine Kinase; Double-Blind Method; Electro | 1999 |
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi | 2000 |
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.
Topics: Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Stud | 2000 |
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Topics: Adult; Aged; Clinical Protocols; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; | 2000 |
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administ | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Topics: Aged; Anticoagulants; Endpoint Determination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Hep | 2002 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombin III; Biomarkers; Drug Administration Schedu | 2003 |
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
Topics: Aged; Angina Pectoris, Variant; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Female; He | 2005 |
Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Colonoscopy; Disease Progression; Dose-Response Relationship, Drug; Doub | 2007 |
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early A
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Disease; Coronary Ves | 1996 |
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
Topics: Anticoagulants; Death, Sudden; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; M | 1997 |
[Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Division; Coronary Angiography; Coronary Disease; | 1997 |
[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin].
Topics: Aged; Angiography, Digital Subtraction; Anticoagulants; Arterial Occlusive Diseases; Dose-Response R | 1999 |
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Topics: Acute Disease; Anticoagulants; Biomarkers; Blood Coagulation Factors; Heparin; Heparin, Low-Molecula | 2002 |
Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
Topics: Aged; Anticoagulants; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenou | 2014 |
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Topics: Aged; Body Weight; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Heparin, Low-Molec | 2003 |
Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Body Weight; Cohort Studies; Female; Hemorrhage; Heparin | 2000 |
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dose-Response Relationsh | 2001 |
Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Topics: Aged; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; M | 2001 |
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasm | 2017 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage | 2018 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem | 2019 |
Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
Topics: Acute Disease; Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Drug Ad | 2014 |
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Topics: Aged; Anticoagulants; Canada; Dalteparin; Drug Administration Schedule; Europe; Female; Hemorrhage; | 2015 |
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Ne | 2015 |
Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Heparin, | 2016 |
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood F | 2003 |
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
Topics: Adult; Anticoagulants; Birth Weight; Circadian Rhythm; Dalteparin; Diastole; Female; Fetal Growth Re | 2005 |
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontan | 1994 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2000 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog | 2000 |
[Low molecular weight heparin (dalteparin) in treatment of patients with thromboembolism incidents].
Topics: Aged; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up | 2001 |
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Dalteparin; Female; Fibrinolysis; Heparin; He | 2002 |
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fibrinolytic Agent | 2018 |
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma | 2015 |
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinoly | 2017 |
A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
Topics: Acenocoumarol; Administration, Oral; Age Factors; Anticoagulants; Female; Fibrin Fibrinogen Degradat | 2009 |
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.
Topics: Administration, Oral; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Home Care Services | 2009 |
Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Aged; Blood Pressure; Female; Heparin, Low-Molecular-Weight; Humans; Hypertension; Male; Recurrence; | 2011 |
Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Fema | 2005 |
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Topics: Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weig | 2007 |
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Hepari | 1997 |
96 other studies available for dalteparin and Recrudescence
| Article | Year |
|---|---|
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.
Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infec | 2020 |
[Digital ischemia in a gardener: is rose cutting a vascular risk factor?].
Topics: Alprostadil; Aneurysm; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Finger Injuries; Fi | 2008 |
Late onset of clinical symptoms and recurrent ecchymotic skin lesions in a 12-year-old girl with a severe double heterozygous protein C deficiency.
Topics: Age of Onset; Anticoagulants; Child; Coumarins; DNA Mutational Analysis; Ecchymosis; Family Health; | 2004 |
Prognostic factors and therapeutic outcome of isolated symptomatic middle cerebral artery stenosis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Constriction, Pathologic; Female; Humans; Infarction | 2005 |
A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.
Topics: Aged, 80 and over; Anticoagulants; Fibrinolytic Agents; Hospitalization; Humans; Infarction, Middle | 2006 |
'Syringe-in-the-pocket'--a new approach to the outpatient thromboembolic prophylaxis of recurrent atrial fibrillation.
Topics: Aged; Ambulatory Care; Atrial Fibrillation; Electric Countershock; Feasibility Studies; Female; Fibr | 2007 |
[Comparative study of the efficacy of a low dose of antivitamin K and a preventive dose of low molecular weight heparin in the prevention of relapses of deep venous thrombosis after curative treatment in the aged subject].
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Inde | 1994 |
[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Evaluation; Female; Heparin; Humans; Male; Middl | 1993 |
Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cohort Studies; Disease-Free Survival; Female; Foll | 2001 |
Secondary prophylaxis with low molecular weight heparin: the dose?
Topics: Acenocoumarol; Anticoagulants; Dose-Response Relationship, Drug; Drug Costs; Enoxaparin; Heparin; He | 2001 |
Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Bandages; Combined Modality Therapy | 2001 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study.
Topics: Aged; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; P | 2020 |
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bi | 2020 |
A Pregnant Woman With Shortness of Breath.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cesarean Section; Dyspnea; Echocardio | 2021 |
Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Neoplasms; Recurrence | 2021 |
The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Enoxapar | 2021 |
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
Topics: Adult; Aged; Algorithms; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; | 2021 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Spontaneous liver rupture associated with anticoagulant therapy A case report.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fatal Outcome; Hematoma; Hepatectomy; Humans; | 2017 |
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Hepar | 2018 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Daltep | 2017 |
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Substitution; Enoxaparin; Factor Xa Inhi | 2019 |
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Age | 2018 |
Sports Injury or Venous Thrombosis?
Topics: Adolescent; Anticoagulants; Arm; Arthralgia; Athletic Injuries; Compression Bandages; Diagnosis, Dif | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabig | 2019 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; | 2014 |
A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations.
Topics: Afibrinogenemia; Amputation, Surgical; Anemia; Anticoagulants; Blood Coagulation Tests; Disease Prog | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Topics: Anticoagulants; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; H | 2015 |
Recurrent Anaphylaxis Due to Enoxaparin.
Topics: Anaphylaxis; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Recurrence | 2015 |
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Hormonal; Drug Synergism; Enoxaparin; Estrogen Replacem | 2016 |
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination; | 2016 |
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Age | 2017 |
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Europe; Female; Hemor | 2017 |
Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Enoxa | 2016 |
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Humans; Male; Neoplasms; | 2017 |
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.
Topics: Administration, Oral; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Kidney | 2017 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Dr | 2009 |
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Direct Service Costs; Drug Costs; Enoxaparin; Health Care Cos | 2008 |
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.
Topics: Anticoagulants; Child, Preschool; Complement Factor H; Enoxaparin; Hemolytic-Uremic Syndrome; Hetero | 2009 |
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibr | 2009 |
[Postoperative ischemic acute stroke and thrombolytic therapy].
Topics: Acute Disease; Aged; Anticoagulants; Aphasia, Broca; Aspirin; Cholesteatoma; Ear Diseases; Ear, Exte | 2009 |
Hypertriglyceridaemia-induced acute pancreatitis due to patient non-compliance.
Topics: Acute Disease; Adult; Analgesics, Opioid; Enoxaparin; Female; Gemfibrozil; Humans; Hypertriglyceride | 2009 |
[Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap].
Topics: Acenocoumarol; Acute Coronary Syndrome; Anterior Wall Myocardial Infarction; Anticoagulants; Coronar | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pu | 2011 |
Outpatient management of pulmonary embolism.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Hospitalization; H | 2011 |
[Improving recanalization of deep veins and the "outcomes" of venous thromboembolic complications in prolonged therapy with enoxaparin].
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle | 2010 |
Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Endoscopy, Gastrointestinal; Enoxaparin; Esophageal a | 2012 |
Foam sclerotherapy with enoxaparin prophylaxis in high-risk patients with postthrombotic syndrome.
Topics: Anticoagulants; Combined Modality Therapy; Drug Administration Schedule; Enoxaparin; Humans; Polidoc | 2013 |
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Topics: Anticoagulants; Antithrombin III; Catheters, Indwelling; Cohort Studies; Coronary Disease; Dose-Resp | 2003 |
Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis?
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
Topics: Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Multicen | 2005 |
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Co | 2005 |
[Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study].
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Inc | 2005 |
[Thromboembolisms endanger the internist patients, too: who needs heparin].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Family Practice; Female; Fibrinolytic Age | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari | 2006 |
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Therapy, C | 2006 |
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-W | 2007 |
Bilateral axillary vein thrombosis in a young patient with lupus anticoagulant and clavicular bone spurs.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Axillary Vein; Clavicle; Enoxaparin; Humans; | 2007 |
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Topics: Adult; Disease Progression; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Heparin, Low-Molecu | 2008 |
Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Confounding Factors, Epidemiologic; Cont | 2008 |
Home treatment of deep venous thrombosis.
Topics: Anticoagulants; Enoxaparin; Home Nursing; Humans; Injections, Intravenous; Randomized Controlled Tri | 1996 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev | 1997 |
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
Topics: Animals; Anticoagulants; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-R | 1998 |
Pursuing progress in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxapa | 1999 |
Risk factors and management of patients with upper limb deep vein thrombosis.
Topics: Activated Protein C Resistance; Adult; Aged; Antithrombin III Deficiency; Drug Therapy, Combination; | 2000 |
Concomitant use of eptifibatide and enoxaparin in the medical management of a patient with a non-ST segment elevation acute coronary syndrome and in-stent restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combina | 2000 |
Low molecular weight heparin in prevention of restenosis after PTCA.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Coronary Angiography; Coronary Disease; DNA | 1996 |
Porous balloon delivery of low molecular weight heparin in the dog coronary artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Catheterization; Coronary Thrombosis; Coronary Vessels; Dog | 1996 |
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
Topics: Anticoagulants; Body Weight; Clinical Trials as Topic; Fibrinolytic Agents; Hemorrhage; Heparin; Hep | 2003 |
Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients.
Topics: Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Portal Vein; Rec | 2023 |
[Antithrombotic Treatment of Pulmonary Embolism].
Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinoly | 2020 |
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous | 2020 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H | 2018 |
VTE and anti-coagulation therapy in cancer patients.
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dalteparin; Factor Xa Inhibitors; Human | 2019 |
Lessons from recurrent deep vein thrombosis in Glanzmann thrombasthenia.
Topics: Aged; Dalteparin; Female; Fibrinolytic Agents; Humans; Platelet Membrane Glycoprotein IIb; Recurrenc | 2013 |
Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Topics: Adult; Anticoagulants; Dalteparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Injections, | 2014 |
Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.
Topics: Adult; Anticoagulants; Brain Ischemia; Dalteparin; Female; Foramen Ovale, Patent; Humans; Injections | 2014 |
Heartache and bellyache: limited English proficiency perpetuating recurrent thromboembolic events.
Topics: Anticoagulants; Communication Barriers; Dalteparin; Female; Humans; Language; Medication Adherence; | 2015 |
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Topics: Anticoagulants; Austria; Cost-Benefit Analysis; Dalteparin; Female; France; Humans; Male; Middle Age | 2017 |
Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?
Topics: Adult; Anti-Bacterial Agents; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome | 2013 |
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Topics: Anticoagulants; Cohort Studies; Dalteparin; Hemorrhage; Humans; Prospective Studies; Pulmonary Embol | 2002 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Dalteparin; Female; Humans; Internation | 2005 |
Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
Topics: Animals; Dalteparin; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination | 1994 |
A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis.
Topics: Actins; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Antibiotics, Antineoplastic; Antineopl | 1995 |
Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Arm; Catheterization, Central Venous; C | 1999 |
[Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy].
Topics: Adolescent; Adult; Antithrombin III; Dalteparin; Dose-Response Relationship, Drug; Female; Fibrin Fi | 2002 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-W | 2015 |
[An image of vena cava thrombosis].
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Angiogenesis Inhibitors; Fibrinolytic Agents; Heart A | 2009 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
[Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Leak S | 2007 |
The outcome of ambulatory DVT management using a multidisciplinary approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Disease Management; Drug Evaluation; Fe | 2001 |